Chronic Idiopathic Urticaria

The study addresses safety concerns related to the risk of keratinocyte carcinoma for patients with atopic dermatitis.

Older, white patients and those who use linagliptin are at a higher risk of bullous pemphigoid.

A new phase 2b trial shows the investigative therapy significantly improves the rate of patients with hives control over 12 weeks versus its competitor.

In a real-world setting, omalizumab improved UAS scores, DLQI scores, response scores, and saw a similar or better safety profile.

A novel cross-cultural adaptation of the Urticaria Control Test (UCT) for clinical applications in Thailand proved every bit as effective as its German predecessor.

Researchers evaluated the correlation between clinical and laboratory findings to identify biomarkers for a range of chronic spontaneous urticaria criteria including differential diagnosis, activity, duration, patient subgroups allocation, and response to treatment.

Researchers compiled best practices for clinicians diagnosing and treating aquagenic urticaria (AU), a rare, but debilitating form of the skin disorder that leaves patients unable to bathe, sweat, or cry without breaking out in painful wheals.

A new study reported no increased incidence of heart disease in patients treated for chronic urticaria, despite prior research highlighting a potential association with other cardiac risk precursors.

ASP0892 is an investigational DNA vaccine for the common, potentially fatal allergy.

Citing health hazards to patients and workers, the US Food and Drug Administration has issued a final rule banning the use of powdered exam gloves and surgical gloves. It will take effect January 19, 2017.

Researchers highlight a new set of tests that could streamline the process involved in identifying autoimmune chronic urticaria.

Chronic idiopathic urticaria (CIU) typically lasts one to five years. Nevertheless, in 14% of CIU patients, the disease lasts longer than five years, and few predictors of its remission rate are available. However, a pair of Thai investigators recently showed that the results of two simple skin tests could predict two-year remission rates in patients with CIU.

Vicki Lawrence, the Carol Burnett Show actress and singer behind "The Night the Lights Went Out in Georgia," recently became a spokeswoman for a sponsored chronic idiopathic urticaria resource, and spoke in a new interview about the self-blame associated with skin diseases.

Patients who have either chronic idiopathic urticaria (CIU) or chronic spontaneous urticaria (CSU) who take oral corticosteroids (OCS) face a greater risk of side effects as well as higher total healthcare costs, according to a recent study.

It appears that 300 mg of omalizumab (Xolair/Genentech) is effective in reducing angioedema, according to the results of a new study.

Children that develop atopic dermatitis – or eczema – from foods are more susceptible to harsh allergic reactions from hives to life-threatening anaphylaxis.

College kids who break out or get hives can, in fact, blame some of their skin problems on heightened levels of psychological stress.

A study in Drug Design, Development, and Therapy provides further evidence that omalizumab is safe and effective for treatment of chronic spontaneous urticaria (CSU). Omalizumab is currently used to treat adult and pediatric patients with asthma and is FDA-approved for use in patients with CSU refractory to antihistamines. These results further outline the effectiveness of the drug in treating CSU and suggest a bump for omalizumab in the typical treatment protocol for CSU.

Researchers have shown there is a connection between personality characteristics and certain dermatological conditions, most notably in psoriasis and atopic dermatitis. Incorporating the information into your practice involves being at least somewhat aware of psychological factors that may contribute to these conditions.

Evidence shows that patients with chronic urticaria have autoimmunity, reduced basophil number and function, and precedent or concurrent infections.

Researchers have been investigating potential mechanisms involved in the generation of urticarial lesions, the role of IgE-targeting in allergic diseases, and the clinical characteristics of chronic spontaneous urticaria.

Clinicians have several guidelines, algorithms, and other tools at their disposal that can assist them in the differential diagnosis and management of chronic urticaria.

Due to its ambiguous etiology, the low cost-to-benefit ratio associated with many laboratory tests used in assessment and diagnosis, and the low-to-moderate strength of evidence supporting many pharmacologic approaches to treatment, chronic urticaria can be one of the most difficult inflammatory skin conditions for clinicians to manage.

A review of the various guidelines on the treatment of chronic urticaria shows there is limited evidence demonstrating the efficacy of many commonly used medications, with the strongest evidence supporting the use of one or more second-generation antihistamines.

Research shows that although mast cells are key effector cells in the pathogenesis of urticaria, targeting individual mast cell mediators is often not therapeutically effective